Medical Science News

RSS

CDI's iCell Cardiomyocytes named to MIT Technology Review's Annual 10 Emerging Technologies List

Cellular Dynamics International (CDI) today announced that CDI's development and commercialization of human cardiomyocytes for drug discovery and toxicity testing, based on the work of CDI co-founder and chief scientific officer, James A. Thomson, Ph.D., on induced pluripotent stem cell (iPSCs) technology, have been named to the MIT Technology Review's Annual 10 Emerging Technologies List.

21 Apr 2010

NCGR deploys Isilon scale-out NAS to power genome sequencing research services

Isilon Systems today announced that the National Center for Genome Resources has deployed Isilon scale-out NAS to power its full range of next-generation genome sequencing research services. By combining Isilon's X-Series, Backup Accelerator and CommVault's Simpana backup software, NCGR has unified eight Illumina Genome Analyzers onto a highly reliable, central storage resource, accelerating time-to-results and ensuring its research information is secure and accessible 24x7x365.

21 Apr 2010

Study helps understand molecular mechanism underlying taurine's protection against hepatic fibrosis

Hepatic fibrosis (HF) occurs in most types of chronic liver diseases and approximately 25%-40% of HF cases may ultimately progress to hepatic cirrhosis. Hepatic stellate cells (HSCs) contribute significantly to the occurrence of HF and the activation of HSC is the key issue in the pathogenesis of HF. Taurine is a kind of important anti-injury substance in the body.

21 Apr 2010

Inovio Biomedical wins Vaccine Industry Excellence Award in “Best Early Stage Biotech” category

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that the company was awarded a Vaccine Industry Excellence Award in the category of "Best Early Stage Biotech" by a panel of judges composed of a broad selection of biotech industry stakeholders. The award was presented at the World Vaccine Congress being held April 19 - 22, 2010, in Washington, D.C.

21 Apr 2010

Alchemia’s HyACT tumour targeting technology enhances killing of cancer stem cells

Alchemia's subsidiary Alchemia Oncology today presented two posters at the American Association of Cancer Research (AACR) 101st Annual Meeting in Washington, DC. The data demonstrates the ability of the Company's HyACT tumour targeting technology to dramatically enhance the killing of cancer stem cells. These cells are highly resistant to treatment with chemotherapeutic drugs and are believed to be responsible for treatment failure and disease recurrence.

21 Apr 2010

Touch Bionics wins Queen's Awards for Enterprise in Innovation category for 2010

Touch Bionics, developer of advanced upper-limb bionic technologies, today announced it is a winner of the prestigious Queen's Awards for Enterprise with an award in the Innovation category for 2010. The Queen's Awards for Enterprise are the UK's most prestigious awards for business performance.

21 Apr 2010

Posit Science challenges BBC study on cognitive training programs

Posit Science, the leader in clinically proven brain fitness programs, contests the interpretation and methodology used in a British Broadcasting Corporation-sponsored study published in the journal Nature.

21 Apr 2010

MicroRNAs control levels of Myc protein in Drosophila: Researchers

In all cancers, whether in kidney, breast, lung, colon, skin or any other tissue, cells show high Myc protein levels. Excess Myc causes cells to multiply in an exaggerated manner, giving rise to the development of tumours. One of the most pressing questions about Myc is how healthy cells keep the expression of this protein in check.

21 Apr 2010

Ajinomoto AminoScience introduces new resource for peptides

Ajinomoto AminoScience, LLC announced today the launch of AjiPhase™, an evolution of liquid phase peptide synthesis containing the benefits of solid and liquid phase methodologies. This new service is designed as an innovative tool that will enable pharmaceutical companies to expand their development pipeline and provide a uniform production process through the entire development lifecycle.

21 Apr 2010

Immunomedics' blood assay for PAM4-protein can detect pancreatic cancer and predict early relapse

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that a new blood test using the Company's proprietary humanized antibody, clivatuzumab or PAM4, predicted a partial response in an initial set of patients treated with a combination of the antibody labeled with yttrium-90 (Y-90) and gemcitabine. Results were presented at the 101st Annual Meeting of the American Association for Cancer Research.

21 Apr 2010

ARIAD presents AP26113 investigational ALK inhibitor preclinical study data at AACR annual meeting

ARIAD Pharmaceuticals, Inc. today announced results of preclinical studies on its investigational anaplastic lymphoma kinase (ALK) inhibitor - AP26113 - showing potent inhibition of the target protein and of mutant forms that are resistant to the first-generation ALK inhibitor, which currently is in clinical trials in patients with cancer. ARIAD scientists presented these data today at the annual meeting of the American Association for Cancer Research (AACR) in Washington, D.C.

21 Apr 2010

Immunomedics reports study results of antibody-SN-38 conjugates for targeted cancer chemotherapy

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, reported today at the 101st Annual Meeting of the American Association for Cancer Research (AACR) results from two studies aimed at improving the design of antibody-SN-38 conjugates for targeted cancer chemotherapy.

21 Apr 2010

EGFR levels may help early detection of breast cancer

Levels of epidermal growth factor receptor (EGFR) may be elevated in the blood of women within 17 months prior to their breast cancer diagnosis, according to findings presented at the American Association for Cancer Research 101st Annual Meeting 2010, held here April 17-21.

21 Apr 2010

Researchers demonstrate role of HSP-90 in portal hypertension

Neural vasoregulation represents a rapid and potent mode of altering vascular tone but has not been investigated thoroughly during portal hypertension. Heat shock protein-90 is well-known to act as a molecular chaperone optimizing endothelial and neural NO-synthase enzyme activity and thus, NO production.

21 Apr 2010

Findings may illuminate how cancer forms and migrates

Rho proteins have been described as "molecular switches" and play a role in cell migration, cell proliferation, cell death, gene expression, and multiple other common cellular functions.

21 Apr 2010

MMRC Multiple Myeloma Genomics Initiative presented at AACR 2010

An analysis of 38 myeloma tumor genomes surveyed through extensive next-generation sequencing by the Broad Institute has revealed intriguing recurrent mutations that point to important cellular pathways which contribute to multiple myeloma. These data were revealed during an oral presentation entitled "First Impressions of the Multiple Myeloma Genome" by Todd R. Golub, MD, Director of the Cancer Program at the Eli and Edythe L. Broad Institute.

21 Apr 2010

Researchers discover subunits of GABAB receptors in central nervous system

In the latest issue of the renowned scientific journal "Nature" researchers from the universities of Freiburg and Basel report on their discovery of previously unknown subunits of the GABAB receptors in the central nervous system. GABAB receptors are transmembrane proteins in nerve cells which are of fundamental significance for the functioning of the brain and have great therapeutical and pharmaceutical importance.

21 Apr 2010

Modest weight reduction reverses immune cell damage in obese people with diabetes

Australian scientists have shown for the first time that even modest weight loss reverses many of the damaging changes often seen in the immune cells of obese people, particularly those with Type 2 diabetes.

21 Apr 2010

Plexxikon presents promising preclinical data from PLX3397 in vivo cancer studies

Plexxikon Inc. today announced promising preclinical data from in vivo cancer studies with PLX3397 demonstrating significant reduction in tumor burden, metastatic spread, bone erosion and cancer bone pain. PLX3397 is an oral, selective kinase inhibitor that down-modulates macrophages, microglia, osteoclasts and mast cells, all cell types targeted by this drug candidate. These cell types play a key role in cancer and metastasis.

21 Apr 2010

Vitamin D intake from foods, supplements may not predict relationship between cancer and vitamin D

Vitamin supplements, diet, geographic location, demographic information or lifestyle, independently or in combination, cannot accurately predict vitamin D concentrations in blood, researchers at the University at Buffalo have found.

21 Apr 2010

Medical Science News

CDI's iCell Cardiomyocytes named to MIT Technology Review's Annual 10 Emerging Technologies List

NCGR deploys Isilon scale-out NAS to power genome sequencing research services

Study helps understand molecular mechanism underlying taurine's protection against hepatic fibrosis

Inovio Biomedical wins Vaccine Industry Excellence Award in “Best Early Stage Biotech” category

Alchemia’s HyACT tumour targeting technology enhances killing of cancer stem cells

Touch Bionics wins Queen's Awards for Enterprise in Innovation category for 2010

Posit Science challenges BBC study on cognitive training programs

MicroRNAs control levels of Myc protein in Drosophila: Researchers

Ajinomoto AminoScience introduces new resource for peptides

Immunomedics' blood assay for PAM4-protein can detect pancreatic cancer and predict early relapse

ARIAD presents AP26113 investigational ALK inhibitor preclinical study data at AACR annual meeting

Immunomedics reports study results of antibody-SN-38 conjugates for targeted cancer chemotherapy

EGFR levels may help early detection of breast cancer

Researchers demonstrate role of HSP-90 in portal hypertension

Findings may illuminate how cancer forms and migrates

MMRC Multiple Myeloma Genomics Initiative presented at AACR 2010

Researchers discover subunits of GABAB receptors in central nervous system

Modest weight reduction reverses immune cell damage in obese people with diabetes

Plexxikon presents promising preclinical data from PLX3397 in vivo cancer studies

Vitamin D intake from foods, supplements may not predict relationship between cancer and vitamin D

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News